A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
To evaluate fludarabine in patients with chronic lymphocytic leukaemia (CLL) not responding to standard treatment. Fludarabine was administered for 5 consecutive days and repeated 4-weekly. Seventeen patients at a single institution were treated. Objective remission was seen in 11 patients. The median survival time was 356 days. Fludarabine is an effective treatment for patients with advanced CLL.